Officinae Bio, part of Maravai LifeSciences

Officinae Bio is now part of Maravai LifeSciences! We are thrilled to announce that Officinae Bio is now part of Maravai LifeSciences! This integration brings together our AI-driven mRNA design expertise with Maravai and TriLink BioTechnologies, part of Maravai LifeSciences industry-leading manufacturing capabilities, accelerating the development of innovative nucleic acid therapies. This collaboration enhances our ability to provide efficient, precise, and scalable solutions for researchers and biotech innovators. We look forward to advancing the field of mRNA therapeutics and supporting the development of life-changing treatments.   🔗 Learn more: https://lnkd.in/eYpRUjKF

Un grande ringraziamento al team editoriale di BeBeez Italia per aver dedicato spazio a questo momento cruciale per Officinae Bio. L'acquisizione da parte di Maravai LifeSciences, leader globale nel settore delle biotecnologie, rappresenta un riconoscimento dell'impegno e dell'innovazione che abbiamo portato avanti negli anni. Questa tappa segna non solo un successo per la nostra azienda, ma anche un passo avanti per il settore biotech italiano, che continua a dimostrare di avere un enorme potenziale competitivo a livello internazionale. 📖 Leggi l'articolo qui: https://lnkd.in/dD6zEDaX 🚀 Guardiamo al futuro con entusiasmo e determinazione! #mRNA #mRNAmedicines #biotech

thank you, San Diego Biotechnology Network, for sharing this milestone! #mRNAmedicines #mRNA #biotech

We are extremely excited to announce that Officinae Bio will be joining the Maravai LifeSciences group of companies. Our guiding principle has always been to create positive, real-world impact quickly. By joining forces with the Maravai and TriLink BioTechnologies, part of Maravai LifeSciences teams we have the unique opportunity to achieve this at scale and speed. Our capabilities complement each other and represent a significant step change in unlocking the potential of mRNA therapeutics. We are incredibly grateful to our customers, advisors, investors and supporters for being with us on this journey. We remain committed to serve our customers and believe we will be able to do this even better. We would particularly like to thank our investors Massimo Portincaso, Deepwave Ventures, Maximilian A. Schwarz, Nucleus Capital, Robert Gibbins, Autonomy Capital, Mario Branciforti for believing in our vision when very few outside us did. The acquisition of Officinae Bio is subject to customary closing conditions and regulatory approvals and is expected to close early in 2025. You can read the full press release here.

🚀 It's not too late! Don’t miss our FREE Webinar! 🚀 Discover how Officinae Bio's smart DNA variant libraries can help you harness AI for faster, more precise antibody synthesis and optimization, unlocking the full potential of AI-driven discovery. We will talk about: 💡The advantages of smart libraries in streamlining drug discovery 💡Case studies on AI-accelerated antibody optimization 💡AI-powered platforms for antibody design 👉 Unlock new possibilities for your research. Register now! https://hubs.ly/Q02VgcKs0 #AI #biotech #DNAlibraries #innovation #antibodydiscovery #webinar #OfficinaeBio

🚀 Less than a week to go! Don’t miss our FREE Webinar! 🚀 Finding the One - Unlocking AI-driven Antibody design with precision DNA libraries, with our CEO, Davide de Lucrezia Learn how we’re transforming AI-generated randomization into precise, combinatorial DNA library design and synthesis that speed up the entire process. Unlock new possibilities for your research. We will talk about: 💡The advantages of smart libraries in streamlining drug discovery 💡Case studies on AI-accelerated antibody optimization 💡AI-powered platforms for antibody design 👉 Unlock new possibilities for your research. Register now! https://hubs.ly/Q02TWZmh0 #AI #biotech #DNAlibraries #innovation #antibodydiscovery #webinar #OfficinaeBio

🚀 Are you ready to take your antibody discovery to the next level? 🚀 At #OfficinaeBio, we build precision #DNAlibraries with sophisticated randomisation schemes. Here’s why partnering with us is a game-changer: 🎯 Unmatched Precision: Achieve unparalleled control over each synthesized variant encoding different subset of amino acids at each position 🏎️ Speed and Efficiency: Rapid turnaround times mean you get your smart DNA Libraries when you need them. ✨ Competitive Pricing: Premium quality without the premium price tag. We’re committed to providing value without compromising on quality. Ready to accelerate your projects? Let’s connect and explore how Officinae Bio can help drive your success Learn more about smart DNA Libraries at our upcoming webinar 👇 https://hubs.ly/Q02SJ_LC0

🌟 Congratulations to the 2024 Nobel Prize in Physiology or Medicine Winners! 🌟 At #OfficinaeBio, we are thrilled to celebrate this year's Nobel Prize in Physiology or Medicine, awarded to Victor Ambros and Gary Ruvkun, for their remarkable contributions to the field of RNA biology and its therapeutic applications. Their groundbreaking research has pushed the frontiers of science, and we are proud to witness the growing global recognition of RNA technologies. As the potential of RNA-based therapies continues to unfold, we remain committed to harnessing this momentum, driving innovation, and shaping the future of healthcare with RNA solutions. This acknowledgment further strengthens our belief in the transformative power of RNA science. 💡🔬 Join us as we continue to explore, innovate, and contribute to the next generation of medical breakthroughs. #NobelPrize #RNARevolution #mRNA #Biotechnology #OfficinaeBio #MedicalInnovation Bibliography: Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993;75(5):843-854. doi:10.1016/0092-8674(93)90529-y 👉 https://lnkd.in/gCPM_mBS Wightman B, Ha I, Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell. 1993;75(5):855-862. doi:10.1016/0092-8674(93)90530-4 👉 https://lnkd.in/dbnuzVER Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kurodak MI, Maller B, Hayward DC, Ball EE, Degnan B, Müller P, Spring J, Srinvasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature. 2000;408(6808):86-89. doi:10.1038/35040556 👉 https://lnkd.in/dpsJH8jd

Ever feel like finding the right DNA variant is like searching for a needle in a haystack? 😫 You’re not alone, and we have the solution! 😎 At #OfficinaeBio, we’re revolutionizing genetic research with our precision DNA variant libraries. Say goodbye to the old "one-size-fits-all" approach. Our tailored libraries ensure you get exactly the amino acid distribution that you need to test. Explore more of what you need and none of what you don't! Ready to take your research to the next level? Let’s connect and see how we can drive your projects forward! 🚀 Oh, and don’t miss our upcoming webinar!👇 https://hubs.ly/Q02R5DDV0 #Biotech #Genomics #PrecisionMedicine #DNAResearch #OfficinaeBio

🚀 Join our FREE Webinar 🚀 Ready to explore how Officinae Bio’s smart DNA variant libraries can transform antibody discovery unlocking the full potential of AI? 🤖✨ Discover how AI-driven design, paired with Officinae Bio’s state-of-the-art gene libraries, can speed up the development of highly precise and optimized antibody therapeutics! 💡 Don’t miss out to see how convert the AI-generated randomisation schemes into physical DNA libraries 👉 Register now! https://hubs.ly/Q02Q4D5T0 #AI #biotech #DNAlibraries #innovation #antibodydiscovery #webinar #OfficinaeBio